{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:20:19Z","timestamp":1787019619295,"version":"build-2736575974"},"reference-count":33,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2011,4,1]]},"DOI":"10.1185\/03007995.2011.555756","type":"journal-article","created":{"date-parts":[[2011,2,14]],"date-time":"2011-02-14T09:42:34Z","timestamp":1297676554000},"page":"847-854","source":"Crossref","is-referenced-by-count":21,"title":["Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers"],"prefix":"10.1185","volume":"27","author":[{"given":"Mark B.","family":"Sostek","sequence":"first","affiliation":[{"name":"AstraZeneca, Wilmington, DE, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Fort","sequence":"additional","affiliation":[{"name":"POZEN Inc., Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"Estborn","sequence":"additional","affiliation":[{"name":"AstraZeneca R&D, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Vikman","sequence":"additional","affiliation":[{"name":"AstraZeneca R&D, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2011,4,5]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.02200.x"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.21907"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.115"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.36013"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03523.x"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.191087"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1002\/art.23929"},{"key":"CIT0008","unstructured":"National Institute for Health and Clinical Excellence. The care and management of osteoarthritis in adults. NICE clinical guideline 59 [online]. Available from http:\/\/www.nice.org.uk\/nicemedia\/pdf\/CG59NICEguideline.pdf [Accessed 3 Jun 2010]"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2007.12.013"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.08.003"},{"issue":"3","key":"CIT0011","first-page":"iii23","volume":"42","author":"Sturkenboom MCJM","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.08.016"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01795.x"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03358.x"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04361.x"},{"key":"CIT0016","unstructured":"Hochberg M, Cryer B, Fort JG, et al. A fixed-dose combination of naproxen and esomeprazole magnesium (VIMOVO\u2122) has comparable efficacy and tolerability to celecoxib in patients with osteoarthritis (OA) of the knee: results from two randomized, controlled trials. Arthritis Rheum 2010;62 (Suppl 10):S388, abs 937"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04378.x"},{"key":"CIT0018","unstructured":"Electronic Medicines Compendium (eMC). Summary of Product Characteristics. VIMOVO 500\u2009mg\/20\u2009mg modified-release tablets [online]. Available from http:\/\/www.medicines.org.uk\/EMC\/medicine\/23883\/SPC\/VIMOVO+500+mg+20+mg+modified-release+tablets [Accessed 19 Nov 2010]"},{"key":"CIT0019","unstructured":"Food and Drug Administration (FDA). VIMOVO\u2122 prescribing information [online]. Available from http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022511lbl.pdf [Accessed 9 Jun 2010]"},{"key":"CIT0020","unstructured":"Pfizer Inc. PhRMA Clinical Study Synopsis: a multi-center, double-blind, parallel group study comparing the incidence of clinically significant upper gastrointestinal events between celecoxib 400\u2009mg BID, and ibuprofen 800\u2009mg TID (N49-98-02-035) or diclofenac 75\u2009mg BID (N49-98-02-102) [online]. Available from http:\/\/www.clinicalstudyresults.org\/documents\/company-study_1841_0.pdf [Accessed 7 Oct 2010]"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.10.1247"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831040-00005"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A104"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200124080-00006"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05905.x"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00499.x"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/821385"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011233432103"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.055012"},{"key":"CIT0030","unstructured":"Centers for Disease Control and Prevention (CDC). Prevalence of Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation - United States, 2007-2009. Morbidity and Mortality Weekly Report [online]. Available from http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm5939a1.htm [Accessed 25 Oct 2010]"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00700.x"},{"issue":"3","key":"CIT0032","first-page":"287","volume":"69","author":"Goldstein JL","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.332.7553.1302"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/03007995.2011.555756","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T17:28:10Z","timestamp":1597771690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1185\/03007995.2011.555756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,1]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4,1]]}},"alternative-id":["10.1185\/03007995.2011.555756"],"URL":"https:\/\/doi.org\/10.1185\/03007995.2011.555756","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,1]]}}}